Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13602125 | 0.86 | EPHX2 (0.58) | EPHX2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL14342809 | 0.85 | EPHX2 (0.51) | EPHX2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL3930409 | 0.84 | EPHX2 (0.66) | EPHX2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL13602141 | 0.80 | CHRM5 (0.50) | ALDH1A1GAANPC1MEN1KMT2A | |
| SCHEMBL13602127 | 0.76 | EPHX2 (0.60) | EPHX2ALDH1A1MEN1KMT2APKM | |
| SCHEMBL3930414 | 0.76 | EPHX2 (0.63) | EPHX2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL14342603 | 0.74 | CHRM5 (0.46) | ALDH1A1GAANPC1MEN1KMT2A | |
| SCHEMBL13602116 | 0.74 | HSD11B1 (0.61) | EPHX2ALDH1A1HSD11B1 | |
| SCHEMBL14342597 | 0.73 | EPHX2 (0.61) | EPHX2ALDH1A1GAANPC1RAB9A | |
| SCHEMBL4556735 | 0.73 | P2RX7 (0.55) | EPHX2KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | EPHX2 2010/4885ALDH1A1 46/4885GAA 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.